Morel I, Cillard J, Lescoat G, Sergent O, Pasdeloup N, Ocaktan A Z, Abdallah M A, Brissot P, Cillard P
Laboratoire de Biologie Cellulaire et Végétale, UFR des Sciences Pharmaceutiques, Rennes, France.
Free Radic Biol Med. 1992 Nov;13(5):499-508. doi: 10.1016/0891-5849(92)90144-6.
The protective effect on iron-supplemented hepatocyte cultures of three iron chelators, pyoverdin Pa and hydroxypyrid-4-one derivatives CP20 and CP22, was compared to that of the widely known desferrioxamine B (Desferal:DFO), on the basis of two criteria: (a) their effectiveness in inhibiting free malondialdehyde (MDA) production as an index of iron-induced lipid peroxidation; and (b) their ability to reduce intracellular enzyme leakage. In view of these two markers of iron toxicity, the protective effect of these chelators was classified as follows: DFO > CP20 > or = CP22 > Pa. The mechanism of cellular protection was elucidated by investigating both the iron-chelating activity and the free radical scavenging property of these agents. As concerns the iron chelation, DFO and Pa exerted the same rank order as for cytoprotection (DFO > Pa). The free radical scavenging property toward hydroxyl radical .OH and peroxyl radical ROO. was investigated in a cell-free experimental model. The two siderophores, DFO and Pa, appeared to have a lower antiradical activity toward .OH than hydroxypyrid-4-one CP22. This .OH scavenging activity was classified as follows: CP22 >> Pa > DFO. Moreover, the chelators exhibited for the quenching of ROO. the same order of effectiveness as that observed for cellular protection: DFO > CP20 > or = CP22 > Pa. These data indicate that, in addition to the iron-chelating activity which represents the most important property for determining the protection capacity of these iron chelators, their free radical scavenging ability also must be taken into account. This direct demonstration of a strong association between the free radical scavenging activity and the protective effect of iron chelators further increases the prospects for the development and clinical applications of new oral chelating drugs.
基于以下两个标准,比较了三种铁螯合剂(绿脓菌素Pa以及羟基吡啶-4-酮衍生物CP20和CP22)对铁补充肝细胞培养物的保护作用与广为人知的去铁胺B(去铁酮:DFO)的保护作用:(a)它们抑制游离丙二醛(MDA)产生的有效性,以此作为铁诱导脂质过氧化的指标;(b)它们减少细胞内酶泄漏的能力。鉴于这两个铁毒性标志物,这些螯合剂的保护作用分类如下:DFO > CP20 ≥ CP22 > Pa。通过研究这些药物的铁螯合活性和自由基清除特性,阐明了细胞保护机制。关于铁螯合,DFO和Pa表现出与细胞保护相同的等级顺序(DFO > Pa)。在无细胞实验模型中研究了对羟基自由基·OH和过氧自由基ROO·的自由基清除特性。两种铁载体DFO和Pa对·OH的抗自由基活性似乎低于羟基吡啶-4-酮CP22。这种·OH清除活性分类如下:CP22 >> Pa > DFO。此外,螯合剂对ROO·猝灭的有效性顺序与细胞保护中观察到的相同:DFO > CP20 ≥ CP22 > Pa。这些数据表明,除了铁螯合活性(这是决定这些铁螯合剂保护能力的最重要特性)之外,还必须考虑它们的自由基清除能力。自由基清除活性与铁螯合剂保护作用之间强关联的这一直接证明,进一步增加了新型口服螯合药物开发和临床应用的前景。